Skip to main content Back to Top
Advertisement

11/26/2019

Telmisartan Tablets

Products Affected - Description

    • Telmisartan tablet, Alembic, 20 mg, bottle, 30 count, NDC 62332-087-30
    • Telmisartan tablet, Alembic, 40 mg, bottle, 30 count, NDC 62332-088-30
    • Telmisartan tablet, Alembic, 80 mg, bottle, 30 count, NDC 62332-089-30
    • Telmisartan tablet, Glenmark, 80 mg, bottle, 30 count, NDC 68462-0201-13
    • Telmisartan tablet, Hikma, 40 mg, bottle, 30 count, NDC 00054-0543-18
    • Telmisartan tablet, Solco Healthcare US, 20 mg, bottle, 30 count, NDC 43541-0283-03
    • Telmisartan tablet, Solco Healthcare US, 40 mg, bottle, 30 count, NDC 43541-0284-03
    • Telmisartan tablet, Solco Healthcare US, 80 mg, bottle, 30 count, NDC 43541-0285-03
    • Telmisartan tablet, Zydus, 20 mg, bottle, 30 count, NDC 68382-0471-78
    • Telmisartan tablet, Zydus, 40 mg, bottle, 30 count, NDC 68382-0472-78
    • Telmisartan tablet, Zydus, 80 mg, bottle, 30 count, NDC 68382-0473-78

Reason for the Shortage

    • Alembic did not provide a reason for the shortage
    • Amneal Pharmaceuticals discontinued telmisartan tablets.
    • Aurobindo refuses to provide information.
    • Cadista discontinued telmisartan tablets.
    • Camber Pharmaceuticals discontinued telmisartan tablets.
    • Glenmark Pharmaceuticals did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Sandoz discontinued telmisartan tablets.
    • Solco Healthcare did not provide a reason for the shortage.
    • Zydus has telmisartan 40 mg tablets on back order and telmisartan 20 mg and 80 mg tablets on allocation due to increased demand.

Available Products

    • Micardis tablet, Boehringer Ingelheim, 20 mg, bottle, 30 count, NDC 00597-0039-37
    • Micardis tablet, Boehringer Ingelheim, 40 mg, bottle, 30 count, NDC 00597-0040-37
    • Micardis tablet, Boehringer Ingelheim, 80 mg, bottle, 30 count, NDC 00597-0041-37
    • Telmisartan tablet, Glenmark, 20 mg, bottle, 30 count, NDC 68462-0199-13
    • Telmisartan tablet, Glenmark, 40 mg, bottle, 30 count, NDC 68462-0200-13
    • Telmisartan tablet, Mylan, 20 mg, bottle, 30 count, NDC 00378-2920-93
    • Telmisartan tablet, Mylan, 20 mg, bottle, 90 count, NDC 00378-2920-77
    • Telmisartan tablet, Mylan, 40 mg, bottle, 30 count, NDC 00378-2921-93
    • Telmisartan tablet, Mylan, 40 mg, bottle, 90 count, NDC 00378-2921-77
    • Telmisartan tablet, Mylan, 80 mg, bottle, 30 count, NDC 00378-2922-93
    • Telmisartan tablet, Mylan, 80 mg, bottle, 90 count, NDC 00378-2922-77
    • Telmisartan tablet, Torrent, 20 mg, bottle, 30 count, NDC 13668-0156-30
    • Telmisartan tablet, Torrent, 20 mg, container, 30 count, NDC 13668-0156-72
    • Telmisartan tablet, Torrent, 40 mg, bottle, 30 count, NDC 13668-0157-30
    • Telmisartan tablet, Torrent, 40 mg, container, 30 count, NDC 13668-0157-72
    • Telmisartan tablet, Torrent, 80 mg, bottle, 30 count, NDC 13668-0158-30
    • Telmisartan tablet, Torrent, 80 mg, container, 30 count, NDC 13668-0158-72

Estimated Resupply Dates

    • Alembic has all preparations of telmisartan tablets on allocation.
    • Glenmark Pharmaceuticals has all preparations of telmisartan tablets on allocation.
    • Hikma has telmisartan 40 mg tablets on allocation.
    • Solco has all preparations of telmisartan tablets on back order and the company cannot estimate a release date
    • Zydus has telmisartan 40 mg tablets on back order and the company estimates a release date of early-December 2019. Zydus has telmisartan 20 mg and 80 mg tablets on allocation.

Updated

Updated November 26, 2019 by Rachael Freeman, PharmD, BCPS. Created October 23, 2019 by Rachael Freeman, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins